Hypoxia-induced tumor malignancy and drug resistance: Role of microRNAs

Biomarkers and Genomic Medicine

Volumn 6, Issue 1, 2014, Pages 1-11

  Liao, Wan Lin ^a   Lin, Shao Chieh ^a   Sunny Sun, H ^a   Tsai, Shaw Jenq ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Drug resistance; Hypoxia; MicroRNAs; Tumor malignancy

Indexed keywords

CULLIN; DEATH ASSOCIATED PROTEIN KINASE; HYPOXIA INDUCIBLE FACTOR; MICRORNA; MICRORNA 100; MICRORNA 107; MICRORNA 15B; MICRORNA 16; MICRORNA 200B; MICRORNA 20A; MICRORNA 210;

ANGIOGENESIS; APOPTOSIS; CELL PROLIFERATION; GENE CONTROL; GLYCOLYSIS; HUMAN; HYPOXIA; HYPOXIA INDUCED TUMOR MALIGNANCY; NEOPLASM; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW;

EID: 84897959821     PISSN: 22140247     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bgm.2014.01.003     Document Type: Review

References (117)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
2. Rana T.M. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007, 8:23-36.
3. Miska E.A. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005, 15:563-568.
4. Croce C.M., Calin G.A. miRNAs, cancer, and stem cell division. Cell 2005, 122:6-7.
5. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
6. Calin G.A., Ferracin M., Cimmino A., et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353:1793-1801.
7. Yanaihara N., Caplen N., Bowman E., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
8. Volinia S., Calin G.A., Liu C.G., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257-2261.
9. Kulshreshtha R., Ferracin M., Wojcik S.E., et al. A microRNA signature of hypoxia. Mol Cell Biol 2007, 27:1859-1867.
10. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.
11. Wang C.-C., Lin S.-C., Li Y.-H., et al. Hypoxia-induced tumor progression and drug resistance: from current understandings to future perspectives. Adapt Med 2012, 4:132-144.
12. Majmundar A.J., Wong W.J., Simon M.C. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010, 40:294-309.
13. Lu X., Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010, 16:5928-5935.
14. Teicher B.A. Hypoxia and drug resistance. Cancer Metastasis Rev 1994, 13:139-168.
15. 2 sensing. Science 2001, 292:464-468.
16. 2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
17. Warburg O. Iron, the oxygen-carrier of respiration-ferment. Science 1925, 61:575-582.
18. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124:269-270.
19. Semenza G.L., Roth P.H., Fang H.M., et al. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994, 269:23757-23763.
20. Sivitz W.I., Lund D.D., Yorek B., et al. Pretranslational regulation of two cardiac glucose transporters in rats exposed to hypobaric hypoxia. Am J Physiol 1992, 263:E562-E569.
21. Kim J.W., Tchernyshyov I., Semenza G.L., et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006, 3:177-185.
22. Papandreou I., Cairns R.A., Fontana L., et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006, 3:187-197.
23. Lu C.W., Lin S.C., Chen K.F., et al. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 2008, 283:28106-28114.
24. Lu C.W., Lin S.C., Chien C.W., et al. Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer. Am J Pathol 2011, 179:1405-1414.
25. Bader A.G., Kang S., Zhao L., et al. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005, 5:921-929.
26. Lee S.H., Lee M.Y., Han H.J. Short-period hypoxia increases mouse embryonic stem cell proliferation through cooperation of arachidonic acid and PI3K/Akt signalling pathways. Cell Prolif 2008, 41:230-247.
27. Lu D.Y., Liou H.C., Tang C.H., et al. Hypoxia-induced iNOS expression in microglia is regulated by the PI3-kinase/Akt/mTOR signaling pathway and activation of hypoxia inducible factor-1α. Biochem Pharmacol 2006, 72:992-1000.
28. Mottet D., Dumont V., Deccache Y., et al. Regulation of hypoxia-inducible factor-1α protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3β pathway in HepG2 cells. J Biol Chem 2003, 278:31277-31285.
29. Chen N., Chen X., Huang R., et al. BCL-xL is a target gene regulated by hypoxia-inducible factor-1α. J Biol Chem 2009, 284:10004-10012.
30. Erler J.T., Cawthorne C.J., Williams K.J., et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004, 24:2875-2889.
31. Yang Y., Sun M., Wang L., et al. HIFs, angiogenesis, and cancer. J Cell Biochem 2013, 114:967-974.
32. Comerford K.M., Wallace T.J., Karhausen J., et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002, 62:3387-3394.
33. Ding Z., Yang L., Xie X., et al. Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J Cancer Res Clin Oncol 2010, 136:1697-1707.
34. Lin S.C., Chien C.W., Lee J.C., et al. Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells. J Clin Invest 2011, 121:1905-1916.
35. Chen L., Feng P., Li S., et al. Effect of hypoxia-inducible factor-1α silencing on the sensitivity of human brain glioma cells to doxorubicin and etoposide. Neurochem Res 2009, 34:984-990.
36. Liu L., Ning X., Sun L., et al. Hypoxia-inducible factor-1α contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 2008, 99:121-128.
37. Zhu H., Chen X.P., Luo S.F., et al. Involvement of hypoxia-inducible factor-1-α in multidrug resistance induced by hypoxia in HepG2 cells. J Exp Clin Cancer Res 2005, 24:565-574.
38. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
39. Ma J., Dong C., Ji C. MicroRNA and drug resistance. Cancer Gene Ther 2010, 17:523-531.
40. Jansson M.D., Lund A.H. MicroRNA and cancer. Mol Oncol 2012, 6:590-610.
41. Garzon R., Calin G.A., Croce C.M. MicroRNAs in Cancer. Annu Rev Med 2009, 60:167-179.
42. Saito Y., Jones P.A. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006, 5:2220-2222.
43. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10:704-714.
44. Munker R., Calin G.A. MicroRNA profiling in cancer. Clin Sci (Lond) 2011, 121:141-158.
45. Ju J.A., Huang C.T., Lan S.H., et al. Characterization of a colorectal cancer migration and autophagy-related microRNA miR-338-5p and its target gene PIK3C3. Biomarkers Genomic Med 2013, 5:74-78.
46. Ju J.A., Huang Y.C., Lan S.H., et al. Identification of colorectal cancer recurrence-related microRNAs. Genomic Med Biomarkers Health Sci 2012, 4:19-20.
47. Iorio M.V., Croce C.M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012, 4:143-159.
48. Kasinski A.L., Slack F.J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011, 11:849-864.
49. Ozsolak F., Poling L.L., Wang Z., et al. Chromatin structure analyses identify miRNA promoters. Genes Dev 2008, 22:3172-3183.
50. Corcoran D.L., Pandit K.V., Gordon B., et al. Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data. PLoS One 2009, 4:e5279.
51. Pocock R. Invited review: decoding the microRNA response to hypoxia. Pflugers Arch 2011, 461:307-315.
52. Loscalzo J. The cellular response to hypoxia: tuning the system with microRNAs. J Clin Invest 2010, 120:3815-3817.
53. Guimbellot J.S., Erickson S.W., Mehta T., et al. Correlation of microRNA levels during hypoxia with predicted target mRNAs through genome-wide microarray analysis. BMC Med Genomics 2009, 2:15.
54. Kulshreshtha R., Ferracin M., Negrini M., et al. Regulation of microRNA expression: the hypoxic component. Cell Cycle 2007, 6:1426-1431.
55. Xu M., Mo Y.Y. The Akt-associated microRNAs. Cell Mol Life Sci 2012, 69:3601-3612.
56. Morin P.J. Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 2003, 6:169-172.
57. Tredan O., Galmarini C.M., Patel K., et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99:1441-1454.
58. Chen H.Y., Lin Y.M., Chung H.C., et al. miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res 2012, 72:3631-3641.
59. Ghosh G., Subramanian I.V., Adhikari N., et al. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. J Clin Invest 2010, 120:4141-4154.
60. Lin S.C., Wang C.C., Wu M.H., et al. Hypoxia-induced microRNA-20a expression increases ERK phosphorylation and angiogenic gene expression in endometriotic stromal cells. J Clin Endocrinol Metab 2012, 97:E1515-E1523.
61. Chan Y.C., Banerjee J., Choi S.Y., et al. miR-210: the master hypoxamir. Microcirculation 2012, 19:215-223.
62. Devlin C., Greco S., Martelli F., et al. miR-210: more than a silent player in hypoxia. IUBMB Life 2011, 63:94-100.
63. Camps C., Buffa F.M., Colella S., et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008, 14:1340-1348.
64. Chen Z., Li Y., Zhang H., et al. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene 2010, 29:4362-4368.
65. Yang W., Sun T., Cao J., et al. Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells invitro. Exp Cell Res 2012, 318:944-954.
66. Grosso S., Doyen J., Parks S.K., et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis 2013, 4:e544.
67. Lee S.T., Chu K., Jung K.H., et al. MicroRNAs induced during ischemic preconditioning. Stroke 2010, 41:1646-1651.
68. Meng F., Henson R., Lang M., et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130:2113-2129.
69. Chan Y.C., Khanna S., Roy S., et al. miR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. J Biol Chem 2011, 286:2047-2056.
70. Hua Z., Lv Q., Ye W., et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006, 1:e116.
71. Dejean E., Renalier M.H., Foisseau M., et al. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia 2011, 25:1882-1890.
72. Xia L., Zhang D., Du R., et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008, 123:372-379.
73. Blick C., Ramachandran A., Wigfield S., et al. Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer. Br J Cancer 2013, 109:50-59.
74. Rane S., He M., Sayed D., et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009, 104:879-886.
75. Ding G., Huang G., Liu H.D., et al. MiR-199a suppresses the hypoxia-induced proliferation of non-small cell lung cancer cells through targeting HIF1α. Mol Cell Biochem 2013, 384:173-180.
76. Inbal B., Cohen O., Polak-Charcon S., et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997, 390:180-184.
77. Choi B.J., Cho Y.G., Song J.W., et al. Altered expression of the KLF4 in colorectal cancers. Pathol Res Pract 2006, 202:585-589.
78. Metzen E., Ratcliffe P.J. HIF hydroxylation and cellular oxygen sensing. Biol Chem 2004, 385:223-230.
79. Hoshino R., Chatani Y., Yamori T., et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999, 18:813-822.
80. Gioeli D., Mandell J.W., Petroni G.R., et al. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999, 59:279-284.
81. Sebolt-Leopold J.S., Dudley D.T., Herrera R., et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors. invivo. Nat Med 1999, 5:810-816.
82. Fan M., Chambers T.C. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat 2001, 4:253-267.
83. McCubrey J.A., Steelman L.S., Chappell W.H., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773:1263-1284.
84. Persons D.L., Yazlovitskaya E.M., Cui W., et al. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 1999, 5:1007-1014.
85. Owens D.M., Keyse S.M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007, 26:3203-3213.
86. Rohan P.J., Davis P., Moskaluk C.A., et al. PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase. Science 1993, 259:1763-1766.
87. Zhang Q., Muller M., Chen C.H., et al. New insights into the catalytic activation of the MAPK phosphatase PAC-1 induced by its substrate MAPK ERK2 binding. J Mol Biol 2005, 354:777-788.
88. Gu T., Ohashi R., Cui R., et al. Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer. Lung Cancer 2009, 66:176-183.
89. Lin M.T., Chang C.C., Chen S.T., et al. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-κB-dependent XIAP up-regulation. J Biol Chem 2004, 279:24015-24023.
90. Huang G., Nishimoto K., Zhou Z., et al. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 2012, 72:908-916.
91. Chow T.F., Mankaruos M., Scorilas A., et al. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol 2010, 183:743-751.
92. He L., Thomson J.M., Hemann M.T., et al. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
93. Hayashita Y., Osada H., Tatematsu Y., et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005, 65:9628-9632.
94. Luo X., Burwinkel B., Tao S., et al. MicroRNA signatures: novel biomarker for colorectal cancer?. Cancer Epidemiol Biomarkers Prev 2011, 20:1272-1286.
95. Chai H., Liu M., Tian R., et al. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin (Shanghai) 2011, 43:217-225.
96. Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007, 62:179-213.
97. Tomlinson D.C., Baldo O., Harnden P., et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007, 213:91-98.
98. L'Hote C.G., Knowles M.A. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 2005, 304:417-431.
99. Siomi H., Siomi M.C. Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell 2010, 38:323-332.
100. He L., He X., Lowe S.W., et al. microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007, 7:819-822.
101. Chang T.C., Yu D., Lee Y.S., et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008, 40:43-50.
102. O'Donnell K.A., Wentzel E.A., Zeller K.I., et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
103. Pillai R.S. MicroRNA function: multiple mechanisms for a tiny RNA?. RNA 2005, 11:1753-1761.
104. Thomson J.M., Newman M., Parker J.S., et al. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 2006, 20:2202-2207.
105. Wulczyn F.G., Smirnova L., Rybak A., et al. Post-transcriptional regulation of the let-7 microRNA during neural cell specification. FASEB J 2007, 21:415-426.
106. Rybak A., Fuchs H., Smirnova L., et al. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol 2008, 10:987-993.
107. Heo I., Joo C., Cho J., et al. Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol Cell 2008, 32:276-284.
108. Chen P.S., Su J.L., Cha S.T., et al. miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. J Clin Invest 2011, 121:3442-3455.
109. Yu F., Yao H., Zhu P., et al. let-7 regulates self-renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
110. Zhang B., Farwell M.A. microRNAs: a new emerging class of players for disease diagnostics and gene therapy. J Cell Mol Med 2008, 12:3-21.
111. Li T., Li D., Sha J., et al. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 2009, 383:280-285.
112. Si M.L., Zhu S., Wu H., et al. miR-21-mediated tumor growth. Oncogene 2007, 26:2799-2803.
113. Ebert M.S., Neilson J.R., Sharp P.A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007, 4:721-726.
114. Ma L., Young J., Prabhala H., et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010, 12:247-256.
115. Kluiver J., Gibcus J.H., Hettinga C., et al. Rapid generation of microRNA sponges for microRNA inhibition. PLoS One 2012, 7:e29275.
116. Trang P., Medina P.P., Wiggins J.F., et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010, 29:1580-1587.
117. Tazawa H., Tsuchiya N., Izumiya M., et al. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A 2007, 104:15472-15477.